Submit your email to push it up the queue
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, is a leading biopharmaceutical company headquartered in the United States. Established in 2001, EMD Serono has made significant strides in the biotechnology sector, focusing on areas such as reproductive health, neurology, and immuno-oncology. With a strong presence in North America and Europe, the company is renowned for its innovative therapies, including cutting-edge treatments for infertility and multiple sclerosis. EMD Serono's commitment to research and development has positioned it as a key player in the biopharmaceutical industry, earning accolades for its contributions to patient care and scientific advancement. Through its unique product offerings and dedication to improving lives, EMD Serono continues to shape the future of healthcare.
How does EMD Serono, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
EMD Serono, Inc.'s score of 59 is higher than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
EMD Serono, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year, as indicated by the absence of reported figures. The company is a current subsidiary of Merck KGaA, which cascades its climate commitments and performance data down to EMD Serono. As part of its parent company's initiatives, EMD Serono aligns with the sustainability goals set by Merck KGaA, which include various reduction targets and commitments to climate action. However, specific reduction targets or achievements for EMD Serono itself have not been detailed in the available data. The absence of direct emissions data suggests that EMD Serono is still in the process of establishing its own specific climate commitments, while relying on the broader framework and initiatives of Merck KGaA. This includes adherence to industry-standard climate terminology and practices, as well as potential participation in initiatives such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are managed at the parent company level. In summary, while EMD Serono, Inc. does not currently report specific emissions data or reduction targets, it is positioned within a corporate family that is actively engaged in climate commitments through its parent company, Merck KGaA.
Access structured emissions data, company-specific emission factors, and source documents
2006 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 352,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | - | - | - | 000,000,000 |
Scope 2 | 402,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | 000,000,000 |
Scope 3 | - | - | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | - | - | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
EMD Serono, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.